Researchers are rapidly examining retatrutide, a innovative treatment developed by Eli Lilly, as a potential advance in weight loss . Unlike many earlier approaches, retatrutide is a dual -action agonist targeting both GLP-1 and GIP, hormones that impact appetite and blood sugar balance. Early re… Read More